AstraZeneca honoured with award from BritCham

AstraZeneca received the award at a ceremony in Ho Chi Minh City in June. On receiving the 'Great Technology & Innovation Award', Atul Tandon, general director of AstraZeneca Vietnam, said, "At AstraZeneca, innovation goes beyond technology – it's about transforming care and making a real difference in people's lives. This recognition is a powerful motivator, encouraging us to collaborate to strengthen healthcare system capacity, and providing equal and affordable access to advanced healthcare in Vietnam."

The British-Swedish AstraZeneca biopharmaceutical company's unwavering commitment is reflected in its consistent top rankings on the Pharmaceutical Innovation and Invention Index, achieving the No.1 position in Invention and No.3 in Innovation for 2023.

AstraZeneca invested a substantial $10.9 billion in research and development (R&D) globally last year, with Vietnam receiving $70 million to conduct clinical trials. AstraZeneca currently supports 65 research studies at nearly 50 hospitals across Vietnam, with over 6,500 patients participating.

Beyond its core focus on R&D for innovative medicines, AstraZeneca prioritises driving healthcare innovation in Vietnam to enhance healthcare access for all. This commitment is exemplified by last year's launch of the Health Innovation Network, a collaborative effort with the Vietnam Young Physician Association, which aims to accelerate the application of AI and digital tools in screening and early detection of common non-communicable diseases.

The 'Health Innovation Network' is operating in Hanoi, Ho Chi Minh City, Danang, Can Tho, and Thua Thien Hue, with over 60 participating hospitals and screening for lung diseases, including lung cancer, for over 100,000 people.

This year, with a focus on lung health and cardiovascular-kidney-metabolic health, the Health Innovation Network will provide free screening and early diagnosis for another 100,000 people and conduct online screening and counselling with AI applications for approximately one million people for non-communicable diseases.

Present in Vietnam since 1994, AstraZeneca has partnered with the government and various other partners for the health and wellbeing of Vietnamese people. In 2023, AstraZeneca and the Ministry of Health signed a pivotal five-year MoU to deepen their long-term partnership and foster comprehensive collaboration in pharmaceutical R&D, manufacture, disease prevention and control, and developing a sustainable healthcare system.

AstraZeneca has implemented various initiatives over the years to promote awareness, prevention, early detection, and effective management of non-communicable diseases, with over 900,000 beneficiaries.

"For three decades, AstraZeneca has consistently prioritised the health of Vietnamese citizens and the sustainability of the healthcare system. We remain committed to this journey, working alongside the government, ministries, and organisations to implement even more ambitious projects with significant impact for the people, communities, and environment of Vietnam," said Nitin Kapoor, chairman of AstraZeneca Vietnam.

As part of a commitment to invest $360 million in Vietnam by 2030, AstraZeneca is dedicating $90 million to facilitate technology transfer for local drug production. This initiative aims to elevate the Vietnamese pharmaceutical industry, ultimately ensuring improved access to high-quality, locally made medicines for patients. Additionally, recognising the interconnection between planetary and human health, AstraZeneca is investing $50 million to restore forests and landscapes in Vietnam, aligning with the country's Net Zero emissions goal by 2050.

AstraZeneca profit up on strong sales of cancer drugs British pharmaceutical giant AstraZeneca on Thursday said net profit jumped 21 percent in the first three months of the year thanks to strong growth in sales of cancer drugs.

AstraZeneca to build 1.5 billion USD cancer drug facility in Singapore British pharmaceutical company AstraZeneca announced on May 20 its intention to build a 1.5 billion USD facility in Singapore to produce new generation cancer treatment drugs.

Nitin Kapoor of AstraZeneca Vietnam appointed MBE Nitin Kapoor, chairman of AstraZeneca Vietnam, has been appointed as a member of the Order of the British Empire (MBE) by His Majesty King Charles for his outstanding contributions to the health sector and international diplomacy.